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activation. The effect of maraviroc intensification has also 
been modest and variable, with several trials showing no 
change in HIV persistence measures.4, 11–13
It is difficult to compare these intensification studies. 
Many had small sample sizes or had varying participant 
demographics, ART regimens and timing, or DNA and 
RNA quantification methods. Furthermore, newer 
generation integrase inhibitors with once daily dosing 
schedules and favourable resistance barriers, such as 
dolutegravir, are supplanting the use of raltegravir in 
many clinics. In the current placebo-controlled trial of 
dolutegravir intensification, Rasmussen and colleagues3 
noted no significant differences in circulating cell-
associated HIV 2-LTR circles, HIV DNA, unspliced RNA, 
or low-level residual plasma RNA between dolutegravir 
intensification or placebo groups. Of note, dolutegravir 
intensification was associated with a paradoxical lower 
level of 2-LTR circles at a single timepoint in a regression 
analysis compared with placebo, but this was transient 
and not recorded in primary outcome repeat measures 
analyses. No major differences in markers of immune 
activation were noted between groups.3
Rasmussen and colleagues3 provide rationale for the 
discrepancy between their dolutegravir intensification 
investigation and the previous studies of raltegravir. For 
example, most participants in the dolutegravir study 
were on a non-nucleoside reverse transcriptase inhibitor-
based regimen, and in contrast to raltegravir, dolutegravir 
concentrations in the gut are only a fraction of those 
in the blood and might not have had as potent of an 
effect in tissue. Furthermore, the dolutegravir study was 
powered to detect a three-fold change in 2-LTR circle 
countrs and small changes might have been missed.
Irrespective of one’s view on residual HIV replication in 
the setting of suppressive ART, three-drug combination 
ART continues to be the mainstay of treatment, with 
the exception of certain scenarios such treatment-
experienced individuals with known or potential 
resistance mutations. Overall, there is little clinical 
momentum to intensify existing regimens with 
additional drug classes. The study by Rasmussen and 
colleagues3 reinforces this notion. However, one suspects 
that pending addition of another antiretroviral drug class, 
a new round of intensification studies will commence.
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Nutritional support to reduce mortality in patients with HIV?
Despite increased access to antiretroviral therapy (ART) 
in patients with HIV, mortality is very high during the 
early months of treatment.1 Immunosuppression and 
undernutrition, presenting as either low body mass 
index (BMI) or micronutrient deficiency, are among 
the key risk factors for increased mortality.2 Several 
clinical trials have investigated the role of micronutrient 
and macronutrient supplementation on HIV-related 
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treatment outcomes including mortality, but many 
have shown no effects or only modest beneficial 
effects.3,4
In The Lancet HIV, Jane Mallewa and colleagues5 
report the results of a large multicentre clinical trial in 
HIV clinics in Kenya, Malawi, Uganda, and Zimbabwe 
in which the researchers tested whether ready-to-
use supplementary food (RUSF) reduced mortality 
in severely immunocompromised patients with HIV 
starting ART. The investigators randomly assigned 
897 adults and children aged at least 5 years to peanut-
based RUSF (1000 kcal per day) and 908 to no-RUSF 
(control) for 12 weeks and followed up for 48 weeks. 
In both groups, individuals received supplementation 
with ready-to-use therapeutic food only when severely 
malnourished (BMI <16–18 kg/m² or BMI-for-age 
Z scores <–3 for children). At 24 weeks, there was no 
effect of the intervention on the primary outcome of 
mortality (hazard ratio 1·05, 95% CI 0·79–1·40, log-rank 
p=0·75). However, the RUSF group had greater gains 
than the control group of weight, BMI, and mid-upper-
arm circumference. These findings echo those from 
three previous large trials: NUSTART, a trial in Tanzania 
and Zambia that showed vitamin and mineral 
supplementation had no effect on mortality at 12 weeks 
after ART initiation, but was associated with an increase 
in CD4 cell counts;6 a Malawian trial testing 14 weeks of 
RUSF versus a corn and soy blend for undernourished 
patients starting ART, which led to increased weight and 
lean mass but had no effect on mortality;7 and a trial of 
a high-dose multivitamin supplement for 24 months 
in patients starting ART in Tanzania, which showed no 
effect on disease progression or mortality.8
The absence of any effect on survival with RUSF5 could 
be a result of several factors, including inadequate 
composition and duration of the intervention. However, 
we believe that one of the most likely reasons is that 
nutritional supplementation doesn’t necessarily achieve 
its aim if given during illness. RUSF fortified with 
micronutrients could theoretically mediate mortality 
reduction by increasing lean mass and immunity and 
modulating metabolic functions. Although there was 
a beneficial effect on lean mass in this trial, this benefit 
might not have been enough to increase survival and 
this inadequate lean mass, coupled with the absence 
of effect on CD4 cell counts could have contributed to 
the overall absence of effect on mortality. Even with 
supplemental micronutrients and macronutrients in 
the intervention group, the acute phase response to 
infection at the beginning of ART might have changed 
nutrient metabolism and hormonal controls rendering 
adequate tissue deposition as well as immunity 
recovery impossible9. In patients with tuberculosis, 
a population with inflammation as severe as that in 
HIV-infected patients, nutritional supplementation did 
not lead to full nutritional recovery because of impaired 
anabolism during treatment.10,11 In Ethiopia, RUSF with 
micronutrients at a concentration of one reference 
nutrient intake, compared with unsupplemented HIV-
infected patients, was associated with a considerable 
increase in lean mass in a subgroup of patients with 
viral suppression,12 but not in those without viral 
suppression, suggesting that reduction of inflammation 
might have contributed to the beneficial effects in the 
viral-suppressed subgroup. Thus, similar mechanisms 
might underlie the results of Mallewa and colleagues’ 
trial5 and previous trials.6–8
In the light of these findings, should nutritional 
supplementation continue to be encouraged in patients 
starting ART? The answer is yes, it is crucial that we 
continue to encourage nutritional support because it 
might increase lean mass, hasten physical and functional 
recovery, and improve work capacity and quality of 
life7,12,13—important attributes in sustaining livelihoods 
of HIV-infected patients in resource-limited settings. 
However, two key questions are which patients should 
receive supplements and when. The evidence from 
Mallewa and colleagues’ study5 suggests that low 
CD4 cell counts should not be used as an indicator for 
supplementation, while findings from other studies 
indicate that low BMI could be used as a marker.7,12 Future 
studies should investigate the appropriate timing for 
initiating nutritional support in HIV-infected patients 
when inflammation has reduced, to help provide a 
scientific basis for further trials of nutritional interventions 
in improving health of HIV-infected patients.
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HIV incidence and scale-up of prevention in western Kenya
As the global scientific community grapples with 
how to achieve HIV elimination in countries where 
the infection is endemic, in their Article in The Lancet 
HIV, Borgdorff and colleagues1 report encouraging 
results. Ever since HIV preventive efficacy of both 
voluntary medical male circumcision (VMMC) and 
antiretroviral therapy (ART) were reported, researchers 
have been increasingly optimistic that scale-up of 
these interventions in a combination strategy might 
lead to population epidemic control.2,3 Borgdorff 
and colleagues aimed to establish the trends in HIV 
infection prevalence and incidence between 2011 
and 2016 in Siaya county, a high HIV burden area 
in western Kenya. From 2011, ART was prescribed 
to HIV-infected individuals with CD4 counts of less 
than 35xlls per µL (WHO stage 1 or 2 disease), and 
from 2014, to HIV-infected individuals with CD4 
counts less than 500 cells per µL. The HIV test and 
start programme strategy were rolled out in 2016. 
Borgdorff and colleagues did secondary analysis on 
programme data and HIV test results collected from 
three population-based HIV surveys (2011, 2012, and 
2016) among participants aged 15–64 years.
HIV prevalence declined by one-third in participants 
aged 15–34 years, but did not change in participants 
aged 15–64 years. HIV incidence declined from 
11·1 (95% CI 9·1–13·1) to 5·7 (4·6–6·9) per 1000 person-
years. Although the declines did not reach the estimated 
threshold for HIV elimination of one case per 1000 person-
years,4,5 the findings indicate positive progress and 
that elimination is possible, especially if the results are 
generalisable in contexts where HIV is endemic. Efforts 
need to be intensified to accelerate and magnify the 
positive trends, and then sustain these effects over time, 
even with possible declining international financial 
support.
Considered in the context of empirical findings of 
the effects of VMMC and ART on HIV incidence,6–9 
the temporal association between rapid scale-up of 
the combination strategy for HIV prevention and 
population-level declines in the incidence of HIV 
infection lends support to a possible cause-and-effect 
relationship between the two.
These findings are based on programmatic data in 
a real-world setting in Kenya. They are comparable 
with the 42% decline in HIV incidence during a 10 year 
scale-up (up to 2016) of HIV combination prevention 
strategy that included VMMC, ART, and voluntary HIV 
testing and counselling in rural Rakai district, Uganda, 
among participants aged 15–49 years in a population 
longitudinal cohort study reported from the Rakai 
Health Sciences Program.10
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